Schering Plans For Possible Clarinex Switch By Readying OTC Division
This article was originally published in The Tan Sheet
Executive Summary
Preparations for a possible Rx-to-OTC switch of Clarinex (desloratadine) will be directed by Schering Consumer Health Care Division Chairman Stanley Barshay
You may also be interested in...
Claritin Hives Relief Approval Could Close Out Rx Product Line
Schering-Plough will not be granted marketing exclusivity for its OTC Claritin Hives Relief,following FDA approval Nov. 19
Claritin Hives Relief Approval Could Close Out Rx Product Line
Schering-Plough will not be granted marketing exclusivity for its OTC Claritin Hives Relief,following FDA approval Nov. 19
Claritin Hives Relief Approval Could Close Out Rx Product Line
Schering-Plough will not be granted marketing exclusivity for its OTC Claritin Hives Relief,following FDA approval Nov. 19